• S1-01. Piccart-Gebhart M, Holmes AP, de Azambuja E, et al: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)
• S1-02. Hurvitz S, Miller JM, Dichmann R, et al: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07)
• S1-03. Slamon DJ, Swain SM, Buyse M, et al: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
• S1-04. Tolaney SM, Barry WT, Dang CT, et al: A phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer
• S1-05. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes indicate trastuzumab benefit in early-stage HER2-positive breast cancer
• S1-06. Denkert C, Loibl S, Salat C, et al: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66)
• S1-07. Adams S, Gray R, Demaria S, et al: Prognostic value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
• S2-01. Kunkler IH, Williams LW, Jack W, et al: The PRIME 2 trial: Wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥ 65 years with early breast cancer managed by breast conservation
• S2-02. Badwe R, Parmar V, Hawaldar R: Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial
• S2-03. Soran A, Ozmen V, Ozbas S: Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer
• S4-04. Vora SR, Kim N, Costa C, et al: Overcoming resistance to PI3K inhibitors in PIK3CA mutant breast cancer using CDK4/6 inhibition: Results from a combinatorial drug screen
• S4-05. Shao Z-M, Jiang Y, Yu K-D: Exome sequencing identifies shift in TP53 and PIK3CA mutation status after paclitaxel-based neoadjuvant chemotherapy in breast cancer
• S4-06. Loibl S, Denkert C, Schneeweis A, et al: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer—prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies
• S5-01. Sikov WM, Berry DA, Perou CM, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
• S5-02. Rugo HS, Olopade O, DeMichele A, et al: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
• S5-04. Mackey JR, Ramos-Vazquez M, Lipatov O, et al: Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
• S5-07. Smerage JB, Barlow WE, Hayes DF, et al: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell levels at first follow-up assessment
• S6-01. Balko JM, Giltnane JM, Schwarz LJ, et al: JAK2 amplifications are enriched in triple negative breast cancers after neoadjuvant chemotherapy and predict poor prognosis
• S6-02. Symmans WF, Wei C, Gould R, et al: Long-term prognostic value of residual cancer burden classification following neoadjuvant chemotherapy
• S1-10. Smith RA, Duffy S, Chen TH-H, et al: Disparities in the estimates of benefits and harms from mammography: Are the numbers really different?
• OT2-01. Malorni L, Sanna G, Pestrin M, et al: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse endocrine resistance - TREnd trial)
• OT2-6-11. von Minckwitz G, Bear H, Bonnefoi H, et al: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)
• OT3-2-11. Chumsri S, Tait N, Shetty J, et al: A phase II study of letrozole and lapatinib followed by an addition of everolimus in postmenopausal women with advanced endocrine resistant breast cancer
• P2-16-20. Clark AS, Lal P, Tan KS, et al: Biomarkers to predict response to the CDK 4/6 inhibitor, palbociclib (PD 0332991) in a single-agent phase II trial in advanced breast cancer ■